Skip to main content
Fig. 5 | Journal for ImmunoTherapy of Cancer

Fig. 5

From: Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Fig. 5

Combined blockade of TGFβR1 with Galunisertib and PD-L1 induce robust regression of murine colon tumors. Mean and individual tumor growth curves for Balb/c mice injected with CT26 tumor cells and treated with galunisertib (75 mg/kg BID for 28 days) and/or anti-PD-L1 antibody (500 μg/dose, q7dx3) when tumors reached ~100mm3 (6 days after implantation). The percentages of CRs were: control (0/15 mice), galunisertib monotherapy (3/14), anti-PD-L1 monotherapy (5/15) and combination therapy (9/14). b Mice which had regressed CT26 tumors after treatment with galunisertib and/or anti-PD-L1 were rechallenged with CT26 tumor cells on the contralateral flank at day 85 post the original tumor challenge. Individual tumor growth curves of secondary CT26 challenge are shown for each treatment group. c Mean and individual tumor growth curves for C57BL/6 mice injected with MC38 tumor cells and treated with galunisertib (75 mg/kg BID for 21 days) and/or anti-PD-L1 antibody (500 μg/dose, q7dx3). Treatment was initiated 3 days after tumor cell implantation. Data shown are representative of two independent experiments with 10–12 mice/group

Back to article page